Cost of New PCSK9 Inhibitors May Overwhelm Patients and Payers

A new class of injectable cholesterol-lowering drugs, PCSK9 inhibitors, are good news for patients who are unresponsive to statins, but their current price. How will payers make this work? Read more here. (Source: Tracey Walker, Managed Healthcare Executive, 9/2/15)

You might also be interested in:

Amgen to Cut Price of Cholesterol Drug by 60% October 26, 2018
ICER Releases Evidence Report on CGRP Inhibitors June 1, 2018
Study: Praluent Not Worth Price January 4, 2019
Article: Price Drops on Praluent, Repatha Boon for Patients February 12, 2019
ICER Releases Final New Evidence Update for Alirocumab February 15, 2019
2018 Specialty Drug Trends February 4, 2019
ICER Releases Final Report on CGRP Inhibitors for Migraine Prevention July 5, 2018